AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04557202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - control group
Trial: NCT01580813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
Trial: NCT00472836
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of CP-945,598 in subjects with normal renal function.
Trial: NCT00472836
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of CP-945,598 in subjects with severe renal impairment.
Trial: NCT00808964
Drug: NU172
RxNorm normalized name: NU172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NU172 administered IV bolus followed by continuous infusion during CABG surgery
Trial: NCT00390221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC injection
Trial: NCT00576615
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
Trial: NCT00970944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily.
Trial: NCT01412372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an inactive pill
Trial: NCT00675064
Drug: GSK369796
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-malarial
Trial: NCT00675064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK369796
Trial: NCT03905564
Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
Trial: NCT03022175
Drug: SPR741
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days.
Trial: NCT03022175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
Trial: NCT05415657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
Trial: NCT02485301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administrated intramuscular
Trial: NCT00972738
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet orally once daily at bedtime for 2 weeks
Trial: NCT02261844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 pill daily X 10 days
Trial: NCT01708629
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered SC
Trial: NCT01413516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill without any active medication
Trial: NCT00532818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin + Topotecan plus placebo
Trial: NCT03426150
Drug: CPP-ACP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The surfaces of specimens were pretreated with CPP-ACP for 3 min
Trial: NCT02185651
Drug: Zavesca® Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.
Trial: NCT02254161
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02254161
Drug: BI 1181181 healthy elderly
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02254161
Drug: BI 1181181 Healthy young
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00006239
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02514850
Drug: Biochaperone Combo
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of BioChaperone Combo
Trial: NCT02514850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of saline 0.9% solution
Trial: NCT03426150
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The surfaces of specimens were pretreated with deionized water for 3 min
Trial: NCT01631305
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 mcg/kg/day
Trial: NCT00060138
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01685411
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
Trial: NCT02833545
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of steroids (diprospan) intra articularly
Trial: NCT00697164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Admission, day 1, day 2 3 days
Trial: NCT04390295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, 24 weeks
Trial: NCT04390295
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, 52 weeks
Trial: NCT01850186
Drug: Stabilized kilnman trio
RxNorm normalized name: Simparica TRIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
Trial: NCT03996148
Drug: Remifentanil, Propofol, and Desflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
Trial: NCT03996148
Drug: Remifentanil, Dexmedetomidine, and Desflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
Trial: NCT03996148
Drug: Remifentanil and Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
Trial: NCT01103726
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets, single dose
Trial: NCT01103726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets, single dose
Trial: NCT01996943
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6% volume/volume ethanol in 0.45% saline solution.
Trial: NCT01996943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo with be 0.45% saline solution (half normal saline).
Trial: NCT02504671
Drug: GSK3196165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Trial: NCT02504671
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
Trial: NCT02504671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
Trial: NCT03049605
Drug: Only medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
Trial: NCT00069511
Drug: UT-231B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03222583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet for oral administration
Trial: NCT03573505
Drug: BG00011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT00811356
Drug: GSK932121; Rosiglitazone; Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
Trial: NCT03829696
Drug: Mifeprex® (Mifepristone 200 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
Trial: NCT02262793
Drug: ASA/ER-DP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00468728
Drug: PAR-101/OPT-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT02982798
Drug: Metformin + Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of Metformin + Rosuvastatin
Trial: NCT01858948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar in shape and color to Omega supplements
Trial: NCT01016093
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
Trial: NCT01016093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00132171
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00505089
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01998672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking solution
Trial: NCT04657926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT03514641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive) tablet to match the active drug
Trial: NCT01857141
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in the control groups received the equivalent volume of normal saline.
Trial: NCT02047175
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20mg 1T PO, QD for 5days
Trial: NCT02047175
Drug: Telmisartan/S-Amlodipine + Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
Trial: NCT01345175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
Trial: NCT02998970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral tablet once daily.
Trial: NCT00324766
Drug: placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 h, infusion
Trial: NCT01145430
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02906930
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily.
Trial: NCT03347422
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
Trial: NCT03097835
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
Trial: NCT03683524
Drug: Current ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To continue with their current ART
Trial: NCT04383236
Drug: Oracure oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
Trial: NCT04198636
Drug: LY01011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Trial: NCT04198636
Drug: Xgeva 120 MG in 1.7 ML Injection
RxNorm normalized name: Xgeva 120 MG in 1.7 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Trial: NCT03679052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
Trial: NCT02868918
Drug: glass ionomer cement
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high viscosity glass ionomer used as a base material
Trial: NCT03402776
Drug: 4th dose of hexavalent vaccine 1 month after the 3rd dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4th dose of hexavalent vaccine 1 month after the 3rd dose
Trial: NCT00784186
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Trial: NCT01659866
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg intramuscularly 2 hours before the procedure
Trial: NCT01659866
Drug: amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/kg intramuscularly 2 hours before the procedure
Trial: NCT01659866
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg intravenously 1 hour before the procedure
Trial: NCT01659866
Drug: amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/kg intravenously 1 hour before the procedure
Trial: NCT01021358
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
Trial: NCT00658749
Drug: AIR645
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Trial: NCT00658749
Drug: Physiologic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Trial: NCT02730351
Drug: Placebo via DISKUS / ACCUHALER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
Trial: NCT02296021
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Trial: NCT00002679
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002679
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00562575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00755404
Drug: PD Solution
RxNorm normalized name: CAPD solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
Trial: NCT00755404
Drug: PD solution containing L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
Trial: NCT04101500
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied only to the control group.
Trial: NCT03365752
Drug: General Anesthetics
RxNorm normalized name: GENERAL ANESTHETICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthetics will be administered intravenously
Trial: NCT03751956
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
Trial: NCT02633488
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 12 week single blind placebos
Trial: NCT00002785
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002785
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002785
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002785
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002785
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03335293
Drug: 100 mcg Epinephrine
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.